http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 03 Sep 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Roper+Technologies+to+present+at+Citi+Technology+Conference/27022393.html <p align="justify">SARASOTA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- <strong>Roper Technologies, Inc. (Nasdaq: ROP)</strong> announced that it is presenting at the Citi Global TMT Conference on Thursday, September 10, 2026, at 8:50 AM (Eastern Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=T3vS7rWeoMnWWxKoX0hY4HWsugfLTMv04iCoYmJsd1cJ9vEpZ68Jrv_PJj6aA8VVoYUz0nr2uH_oUXLYk-aSuy2hInAbPQ9B1MMqM5nC7dI=" rel="nofollow" target="_blank">www.ropertech.com</a>.</p> <p align="justify"><strong>About Roper Technologies</strong></p> <p align="justify">Roper Technologies is a constituent of the Nasdaq 100, S&amp;P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses http://www.streetinsider.com/Press+Releases/Roper+Technologies+to+present+at+Citi+Technology+Conference/27022393.html Thu, 03 Sep 2026 08:30:00 -0400 ROP http://www.streetinsider.com/Globe+Newswire/Roper+Technologies+to+present+at+Citi+Technology+Conference/27022393.html <p align="justify">SARASOTA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- <strong>Roper Technologies, Inc. (Nasdaq: ROP)</strong> announced that it is presenting at the Citi Global TMT Conference on Thursday, September 10, 2026, at 8:50 AM (Eastern Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=T3vS7rWeoMnWWxKoX0hY4HWsugfLTMv04iCoYmJsd1cJ9vEpZ68Jrv_PJj6aA8VVoYUz0nr2uH_oUXLYk-aSuy2hInAbPQ9B1MMqM5nC7dI=" rel="nofollow" target="_blank">www.ropertech.com</a>.</p> <p align="justify"><strong>About Roper Technologies</strong></p> <p align="justify">Roper Technologies is a constituent of the Nasdaq 100, S&amp;P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses http://www.streetinsider.com/Globe+Newswire/Roper+Technologies+to+present+at+Citi+Technology+Conference/27022393.html Thu, 03 Sep 2026 08:30:00 -0400 ROP http://www.streetinsider.com/Press+Releases/Roper+Technologies+to+present+at+Goldman+Sachs+Technology+Conference/27016109.html <p align="justify">SARASOTA, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- <strong>Roper Technologies, Inc. (Nasdaq: ROP)</strong> announced that it is presenting at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026, at 8:10 AM (Pacific Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=VvIByfZz3U-UlRhGbFAKl4USyVjopHSetgn-8MMy6jsJnz4raYroj_o3OEAalExVSDbYNRcCJZbeTu1Osm43elh5vwblIIgfD0TymiqeP4M=" rel="nofollow" target="_blank">www.ropertech.com</a>.</p> <p align="justify"><strong>About Roper Technologies</strong></p> <p align="justify">Roper Technologies is a constituent of the Nasdaq 100, S&amp;P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market http://www.streetinsider.com/Press+Releases/Roper+Technologies+to+present+at+Goldman+Sachs+Technology+Conference/27016109.html Wed, 02 Sep 2026 08:30:00 -0400 ROP http://www.streetinsider.com/Globe+Newswire/Roper+Technologies+to+present+at+Goldman+Sachs+Technology+Conference/27016109.html <p align="justify">SARASOTA, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- <strong>Roper Technologies, Inc. (Nasdaq: ROP)</strong> announced that it is presenting at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026, at 8:10 AM (Pacific Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=VvIByfZz3U-UlRhGbFAKl4USyVjopHSetgn-8MMy6jsJnz4raYroj_o3OEAalExVSDbYNRcCJZbeTu1Osm43elh5vwblIIgfD0TymiqeP4M=" rel="nofollow" target="_blank">www.ropertech.com</a>.</p> <p align="justify"><strong>About Roper Technologies</strong></p> <p align="justify">Roper Technologies is a constituent of the Nasdaq 100, S&amp;P 500, and Fortune 500. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market http://www.streetinsider.com/Globe+Newswire/Roper+Technologies+to+present+at+Goldman+Sachs+Technology+Conference/27016109.html Wed, 02 Sep 2026 08:30:00 -0400 ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html <p>Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.</p> <p>The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment http://www.streetinsider.com/FDA/Roche+wins+FDA+nod+for+HER2+companion+diagnostics+in+GEA/26980827.html Wed, 26 Aug 2026 14:52:56 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/Press+Releases/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html <div class="xn-content"> <ul type="disc"><li><b>The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.</b></li><li><b>Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.</b></li><li><b>Together, the tests enable precise assessment of HER2-positive status to help identify patients eligible for treatment with ZIIHERA.</b></li></ul><p><span class="legendSpanClass"><location value="LU/us.az.tucson" idsrc="xmltag.org" >TUCSON, Ariz.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="Swiss:RO" idsrc="xmltag.org">Roche</span> (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY^® HER2 (4B5) and VENTANA^® HER2 Dual ISH DNA http://www.streetinsider.com/PRNewswire/Roche+receives+FDA+approval+for+companion+diagnostic+tests+to+identify+patients+with+HER2-positive+metastatic+gastroesophageal+adenocarcinoma+eligible+for+ZIIHERA/26980826.html Wed, 26 Aug 2026 14:52:00 -0400 A.08801724 O.00222322 O.00268852 RHHBY RO ROG ROP